GlassScriptPhysician profile
Katrina Karpinski
NPI 1295350403
$1,867.23
in general payments reported to CMS, 2019-2025
11 companies · $686 in 2025
The $686 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.29 · 2022: $380 · 2023: $117 · 2024: $654 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $732.65 | 2022-2025 | Miebo, Infuse, Xiidra |
| Amgen INC. | $372.65 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $217.85 | 2022-2023 | Acuvue |
| Coopervision INC. | $151.86 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Astellas Pharma US INC | $121.84 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $110.98 | 2024 | Xdemvy |
| Lkc Technologies, INC. | $66.77 | 2022 | |
| Alcon Vision LLC | $39.91 | 2023-2025 | Precision7, Total30 |
| Genzyme Corporation | $19.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.94 | 2023 | |
| Kala Pharmaceuticals, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Karpinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.